Anhydron

NDA 13157, held by Lilly. Cyclothiazide.

As of Nov 14, 2026, NDA 13157 (Anhydron), held by Lilly, was first approved by FDA on Aug 20, 1963, with 4 approved supplements and 0 published complete response letters.

First approved: Aug 20, 1963
Review: Standard
Supplements approved: 4
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 5 submissions below

Date	Submission	Status	Documents
Aug 20, 1963	Original applicationNew molecular entity · Standard review	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Anhydron2MG · tablet;oral	Cyclothiazide	Discontinued

All 5 submissions, including labeling and manufacturing supplements


Nov 8, 1990	Supplement 12Labeling	Approved	None posted
Sep 21, 1989	Supplement 11Labeling	Approved	None posted
Nov 1, 1985	Supplement 10Labeling	Approved	None posted
Mar 18, 1977	Supplement 7Labeling	Approved	None posted
Aug 20, 1963	Original applicationNew molecular entity · Standard review	Approved	None posted

Identifiers

Application: NDA 13157
Drugs@FDA: Overview at FDA
Company: Lilly

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters